Clinical Outcomes of Patient Subgroups in the TANGO II Study

Tanaya Bhowmick, Tanaya Bhowmick

Abstract

Introduction: Meropenem-vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited applicability to daily medical practice as they often focus on indications such as urinary tract infections or skin and soft tissue infections, which generally have patients with fewer comorbid conditions that the typical patients who develops infection with CRE. The more useful studies are pathogen-focused trials which do not exclude the more complicated subjects with conditions such as renal failure, immunocompromised status, or exposure to prior antibiotic therapy.

Methods: The TANGO II study was an open-label investigation of M-V compared with the best available treatment (BAT) in hospitalized adults with a confirmed infection that was known or suspected to be a CRE infection. TANGO II specifically included patients with comorbidities, prior antibiotic therapy, renal failure, and immunocompromised status that are typical in patients with a CRE infection. Interim data analysis indicated that a significant benefit was seen for those patients receiving M-V over BAT. This analysis reports on subsets of TANGO II study patients with multiple comorbidities and high severity of illness, specifically those with prior antibiotic therapy, renal failure, and immunocompromised status. A patient case that highlights particular complexities and challenges of treating patients with CRE infections in the real world is also presented.

Results: Subjects with comorbid conditions had better outcomes when given M-V rather than BAT.

Conclusion: M-V is a welcome addition to the antibiotic armamentarium for the treatment of severe CRE infections in complicated patients.

Trial registration: ClinicalTrials.gov identifier NCT02168946.

Keywords: Carbapenem-resistant organisms; Meropenem–vaborbactam; Multidrug-resistant organisms; Vabomere.

References

    1. Spellberg B, Bonomo RA. Editorial commentary: ceftazidime-avibactam and carbapenem-resistant Enterobacteriaceae: “we're gonna need a bigger boat”. Clin Infect Dis. 2016;63(12):1619–1621. doi: 10.1093/cid/ciw639.
    1. Joint Commission on Hospital Accreditation. Approved: new antimicrobial stewardship standard. Jt Comm Perspect. 2016;36(7):1–8.
    1. Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). 2020. . Accessed 8 Jul 2019.
    1. Burnham JP, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infect Control Hosp Epidemiol. 2018;40(1):112–113. doi: 10.1017/ice.2018.304.
    1. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. doi: 10.1016/S1473-3099(18)30605-4.
    1. Pani A, Colombo F, Agnelli F, et al. Off-label use of ceftaroline fosamil: a systematic review. Int J Antimicrobial Agents. 2019;54(5):562–71.
    1. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi: 10.1093/cid/ciw636.
    1. Vickery SB, McClain D, Wargo KA. Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa. Pharmacotherapy. 2016;36(10):e154–e159. doi: 10.1002/phar.1825.
    1. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54–60. doi: 10.1111/j.1469-0691.2011.03478.x.
    1. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2015;30(10):972–976. doi: 10.1086/605922.
    1. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2015;29(12):1099–1106. doi: 10.1086/592412.
    1. Jorgensen SCJ, Rybak MJ. Pathogen-specific clinical trials: a new paradigm in clinical trials for multidrug-resistant organisms. Infect Dis Therapy. 2018;7(4):401–405. doi: 10.1007/s40121-018-0215-0.
    1. Peeters P, Ryan K, Karve S, et al. The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection. Infect Drug Resist. 2019;12:329–343. doi: 10.2147/IDR.S184116.
    1. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Therapy. 2018;7(4):439–455. doi: 10.1007/s40121-018-0214-1.
    1. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754–762. doi: 10.1093/cid/ciw378.
    1. Hayden A, et al. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411–420. doi: 10.1016/j.blre.2016.05.001.
    1. Bassetti M, et al. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv Ther. 2019;36(7):1771–1777. doi: 10.1007/s12325-019-00981-y.
    1. Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis. 2017;4(2):ofx063.
    1. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–1283. doi: 10.1093/cid/ciu052.
    1. Mandell D. Bennett's principles and practice of infectious diseases. In: Bennett JE, Dolin R, Blaser MJ, editors. Principles and practice of infectious diseases, 9th edn, vol 3105–3106. Philadelphia: Elsevier; 2019.
    1. Dalrymple LS, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356–363. doi: 10.1053/j.ajkd.2011.07.012.
    1. Tsuji BT, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacother J Human Pharmacol Drug Therapy. 2019;39(1):10–39.
    1. Livornese LL, et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am. 2004;18(3):551–579. doi: 10.1016/j.idc.2004.04.013.
    1. Miano TA, et al. Attributable risk and time course of colistin-associated acute kidney injury. Clin J Am Soc Nephrol. 2018;13(4):542–550. doi: 10.2215/CJN.06980717.
    1. Presentation BPWG (Break Point Working Group). CLSI (Clinical Laboratory Standards Institute). Dallas; 2019.
    1. Carmeli Y, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673. doi: 10.1016/S1473-3099(16)30004-4.
    1. McKinnell JA, et al. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med. 2019;380(8):791–793. doi: 10.1056/NEJMc1807634.
    1. Motsch J, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808.
    1. Paul M, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi: 10.1016/S1473-3099(18)30099-9.
    1. Shields RK, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–e2517. doi: 10.1128/AAC.02497-17.
    1. Shields RK, et al. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4(3):ofx101.
    1. Tumbarello M, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. 2018;68(3):355–364. doi: 10.1093/cid/ciy492.
    1. Göttig S, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74(11):3211–16.
    1. Munoz-Price LS, et al. Patient-to-patient transmission of KPC variants with reduced ceftazidime-avibactam susceptibility. Antimicrob Agents Chemother. 2019:63(10):e00955–19.
    1. Athans V, Neuner EA, Hassouna H, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactram-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2019;63(1):1–8. doi: 10.1128/AAC.01551-18.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅